ERBB2 and cancer: Affibodies are another reagent class used for TRNT for the treatment of HER-2 disposed cancers, with lutetium-177-tagged anti-HER-2 Affibodies demonstrating remarkable inhibition of tumour formation (Tolmachev et al. 2007).